JP2020506162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506162A5 JP2020506162A5 JP2019523734A JP2019523734A JP2020506162A5 JP 2020506162 A5 JP2020506162 A5 JP 2020506162A5 JP 2019523734 A JP2019523734 A JP 2019523734A JP 2019523734 A JP2019523734 A JP 2019523734A JP 2020506162 A5 JP2020506162 A5 JP 2020506162A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- item
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164847A JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414413P | 2016-10-28 | 2016-10-28 | |
| US62/414,413 | 2016-10-28 | ||
| US201762533336P | 2017-07-17 | 2017-07-17 | |
| US62/533,336 | 2017-07-17 | ||
| PCT/US2017/058874 WO2018081642A1 (en) | 2016-10-28 | 2017-10-27 | Anti-apoe antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164847A Division JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506162A JP2020506162A (ja) | 2020-02-27 |
| JP2020506162A5 true JP2020506162A5 (https=) | 2021-02-04 |
| JP7236737B2 JP7236737B2 (ja) | 2023-03-10 |
Family
ID=62024064
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523734A Active JP7236737B2 (ja) | 2016-10-28 | 2017-10-27 | 抗ａｐｏｅ抗体 |
| JP2022164847A Pending JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A Pending JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164847A Pending JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A Pending JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US11124562B2 (https=) |
| EP (1) | EP3532034A4 (https=) |
| JP (3) | JP7236737B2 (https=) |
| AU (2) | AU2017350947B2 (https=) |
| CA (1) | CA3042236A1 (https=) |
| WO (1) | WO2018081642A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042236A1 (en) | 2016-10-28 | 2018-05-03 | Washington University | Anti-apoe antibodies |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
| US12594330B2 (en) | 2019-06-04 | 2026-04-07 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
| CN112538113B (zh) * | 2020-08-06 | 2023-07-21 | 武汉天德生物科技有限公司 | 杂交瘤细胞株ace8及其产生的apoe4点突变单克隆抗体 |
| WO2022047125A1 (en) * | 2020-08-28 | 2022-03-03 | Board Of Regents, The University Of Texas System | Antibodies specific to ccl21 and methods of use |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| US20240400659A1 (en) * | 2021-10-19 | 2024-12-05 | Bioatla, Inc. | Conditionally active proteins for neurodegenerative diseases |
| WO2025049995A1 (en) * | 2023-09-01 | 2025-03-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Anti-ly6 antibodies and uses thereof |
| WO2025219956A1 (en) * | 2024-04-18 | 2025-10-23 | Comed Therapeutics Ltd. | Compositions and methods for rna delivery to cells |
| CN118184783B (zh) * | 2024-05-09 | 2024-07-09 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
| WO2025245146A2 (en) * | 2024-05-20 | 2025-11-27 | Nextcure, Inc. | Anti-apoe antibodies: compositions and methods of making and using the same |
| WO2025258951A1 (ko) * | 2024-06-10 | 2025-12-18 | 주식회사 아델 | 항-아포지단백질 e4(apolipoprotein e4, apoe4) 항체 및 그의 용도 |
| WO2026062579A1 (en) | 2024-09-19 | 2026-03-26 | Comed Therapeutics Ltd. | Compositions and methods for protein delivery to cells |
| CN119147750A (zh) * | 2024-11-15 | 2024-12-17 | 科美诊断技术股份有限公司 | 一种apoe4的光激化学发光检测试剂、试剂盒及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US6313089B1 (en) * | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| WO2001072307A1 (en) * | 2000-03-29 | 2001-10-04 | The J. David Gladstone Institutes | Methods of treating cognitive decline disease conditions with androgens |
| DE60222816T2 (de) | 2001-12-03 | 2008-07-03 | Amgen Fremont Inc. | Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung |
| GB0200757D0 (en) * | 2002-01-15 | 2002-02-27 | Univ Manchester | Diagnostic methods |
| RU2006122946A (ru) * | 2003-11-28 | 2008-01-10 | Астразенека Аб (Se) | Антитела |
| WO2008073300A2 (en) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| EP2542581A4 (en) * | 2010-03-01 | 2014-01-22 | David Gladstone Inst | APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF |
| MX2013006116A (es) * | 2010-12-02 | 2013-10-17 | Univ Washington | Tratamiento de sintomas asociados a placa amiloide. |
| JP2014511174A (ja) * | 2011-02-07 | 2014-05-15 | ネオトープ バイオサイエンシーズ リミテッド | Ａｐｏｅ免疫療法 |
| AU2012359020B2 (en) | 2011-12-19 | 2017-04-13 | The Washington University | Methods for diagnosing Alzheimer's disease |
| US20150140672A1 (en) | 2011-12-19 | 2015-05-21 | Washington University | Methods for detecting amyloid beta amyloidosis |
| EP2847218A4 (en) * | 2012-05-08 | 2015-12-30 | Univ Ramot | APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| EP2923209A4 (en) | 2012-11-20 | 2016-04-27 | Univ Washington | METHOD FOR THE DIAGNOSIS OF DISEASES BY ANALYSIS OF AMYLOID BETA ENRICHMENT KINETICS |
| WO2015187992A2 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| US20170218058A1 (en) | 2016-01-28 | 2017-08-03 | Alector, LLC | Anti-apoe4 antigen-binding proteins and methods of use thereof |
| CA3042236A1 (en) * | 2016-10-28 | 2018-05-03 | Washington University | Anti-apoe antibodies |
-
2017
- 2017-10-27 CA CA3042236A patent/CA3042236A1/en active Pending
- 2017-10-27 US US16/345,637 patent/US11124562B2/en active Active
- 2017-10-27 AU AU2017350947A patent/AU2017350947B2/en active Active
- 2017-10-27 WO PCT/US2017/058874 patent/WO2018081642A1/en not_active Ceased
- 2017-10-27 EP EP17865058.6A patent/EP3532034A4/en active Pending
- 2017-10-27 JP JP2019523734A patent/JP7236737B2/ja active Active
-
2021
- 2021-08-24 US US17/410,686 patent/US11926660B2/en active Active
-
2022
- 2022-10-13 JP JP2022164847A patent/JP2022191397A/ja active Pending
-
2024
- 2024-02-08 US US18/436,678 patent/US12540175B2/en active Active
- 2024-05-10 AU AU2024203123A patent/AU2024203123A1/en active Pending
- 2024-11-05 JP JP2024193660A patent/JP2025023998A/ja active Pending
- 2024-11-08 US US18/942,122 patent/US20250145697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506162A5 (https=) | ||
| AU2021202095B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| JP7236737B2 (ja) | 抗ａｐｏｅ抗体 | |
| JP2022500081A5 (https=) | ||
| US20240117025A1 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
| CA2872928C (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| JP2022500081A (ja) | 抗ｔｒｅｍ−２アゴニスト抗体 | |
| JP2010526028A5 (https=) | ||
| ZA200500068B (en) | Treatment of tnf related disorders | |
| JP2012525128A5 (https=) | ||
| JP2016518411A5 (https=) | ||
| JP2023531069A5 (https=) | ||
| JP2022541459A5 (https=) | ||
| AU2016335929A1 (en) | Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies | |
| JP7610767B2 (ja) | レット症候群の処置のためのセマフォリン４ｄ結合分子の使用 | |
| US20130336961A1 (en) | B Cell Depletion for Central Nervous System Injuries and Methods and Uses Thereof | |
| KR102959210B1 (ko) | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2008531719A5 (https=) | ||
| JP2026504928A (ja) | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 | |
| Warrington et al. | Regeneration strategies for multiple sclerosis |